Mary J. MacKenzie
- Pulmonary and Respiratory Medicine top 0.5%
- Oncology top 1%
- Molecular Biology top 5%
- Cancer Research top 1%
- Radiology, Nuclear Medicine and Imaging top 1%
- Co-authors
- Liji ShenOliver SartorIvo KocákJohann S. de BonoI. BodrogiGwénaëlle GravisMustafa ÖzgüroğluSteinbjørn Hansen
- Topics
- Renal cell carcinoma treatment (34 papers)Cancer Genomics and Diagnostics (23 papers)Renal and related cancers (19 papers)
- Partner nations
- CanadaUnited StatesDenmark
In The Last Decade
Mary J. MacKenzie
67 papers receiving 5.2k citations
Hit Papers
Peers
Comparison fields: 5 of 117
- Pulmonary and Respiratory Medicine 3.9k
- Oncology 2.0k
- Molecular Biology 1.8k
- Cancer Research 1.5k
- Radiology, Nuclear Medicine and Imaging 925
Countries citing papers authored by Mary J. MacKenzie
This map shows the geographic impact of Mary J. MacKenzie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary J. MacKenzie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary J. MacKenzie more than expected).
Fields of papers citing papers by Mary J. MacKenzie
This network shows the impact of papers produced by Mary J. MacKenzie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary J. MacKenzie. The network helps show where Mary J. MacKenzie may publish in the future.
Co-authorship network of co-authors of Mary J. MacKenzie
This figure shows the co-authorship network connecting the top 25 collaborators of Mary J. MacKenzie. A scholar is included among the top collaborators of Mary J. MacKenzie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary J. MacKenzie. Mary J. MacKenzie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 80 | |
| 2 | 21 | |
| 3 | 2 | |
| 4 | 27 | |
| 5 | 113 | |
| 6 | 39 | |
| 7 | 20 | |
| 8 | 64 | |
| 9 | 55 | |
| 10 | 55 | |
| 11 | 67 | |
| 12 | 7 | |
| 13 | 14 | |
| 14 | 35 | |
| 15 | 46 | |
| 16 | 42 | |
| 17 | A phase I study of temsirolimus in combination with metformin in advanced solid tumors | 1 |
| 18 | AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium. | 1 |
| 19 | 56 | |
| 20 | 64 |
About Mary J. MacKenzie
Mary J. MacKenzie is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology, having authored 67 papers that have together received 5.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (34 papers), Cancer Genomics and Diagnostics (23 papers) and Renal and related cancers (19 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.9k citations), Cancer Research (1.5k citations) and Oncology (2.0k citations). Mary J. MacKenzie has collaborated with scholars based in Canada, United States and Denmark. Frequent co-authors include Liji Shen, Oliver Sartor, Ivo Kocák, Johann S. de Bono, I. Bodrogi, Gwénaëlle Gravis, Mustafa Özgüroğlu, Steinbjørn Hansen, Stéphane Oudard and Sunil Gupta. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.